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Abstract Esophageal achalasia is a rare neurodegenerative disease of the esophagus and the lower esophageal sphincter
that presents within a spectrum of disease severity related to progressive pathological changes, most commonly resulting in
dysphagia. The pathophysiology of achalasia is still incompletely understood, but recent evidence suggests that
degeneration of the postganglionic inhibitory nerves of the myenteric plexus could be due to an infectious or autoimmune
mechanism, and nitric oxide is the neurotransmitter affected. Current treatment of achalasia is directed at palliation of
symptoms. Therapies include pharmacological therapy, endoscopic injection of botulinum toxin, endoscopic dilation, and
surgery. Until the late 1980s, endoscopic dilation was the first line of therapy. The advent of safe and effective minimally
invasive surgical techniques in the early 1990s paved the way for the introduction of laparoscopic myotomy. This review
will discuss the most up-to-date information regarding the pathophysiology, diagnosis, and treatment of achalasia, including
a historical perspective. The laparoscopic Heller myotomy with partial fundoplication performed at an experienced center is
currently the first line of therapy because it offers a low complication rate, the most durable symptom relief, and the lowest
incidence of postoperative gastroesophageal reflux.
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Introduction
Esophageal achalasia is a rare neurodegenerative disease of
the esophagus and lower esophageal sphincter (LES) that
leads to dysphagia and other associated symptoms. The
incidence of achalasia in western populations is one to three
per 100,000 people.
1,2 Patients with achalasia present to the
gastroenterologist within a spectrum of disease severity
related to the progressive pathological changes affecting the
esophagus, such as grades of esophageal dilation, and
associated conditions, such as esophageal diverticulum.
3
Because achalasia is rare and the spectrum of disease
severity is wide, few randomized controlled clinical trials
have properly delineated the best treatment strategy. The
safety, effectiveness, and durability of current treatment
options, including pharmacologic, endoscopic, and surgical
therapy, varied widely. Until the late 1980s, endoscopic
dilation was considered first-line therapy;
4 but after
minimally invasive surgical techniques were introduced
toward the end of the last century, expert opinion shifted.
Currently, most experts agree that first-line therapy should
be laparoscopic myotomy with partial fundoplication,
performed by an experienced surgeon, and that endoscopic
methods should be reserved as an alternative to surgery for
patients who are poor surgical candidates, refuse an
operation, and possibly patients for whom surgery fails.
5–13
In this paper, we review the current understanding of the
pathophysiology of achalasia, standard and emerging
diagnostic tools, and outline the various treatment options
before and after the development of minimally invasive
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Pathophysiology
Achalasia, though rare, is possibly the most studied and best
described motility disorder of the esophagus, yet its
pathogenesis remains incompletely understood. It is a
neurodegenerative disorder affecting the function of the
muscle of the esophageal body and LES, as well as the vagal
trunks and dorsal vagal nuclei.
14 The pathogenesis stems
from an idiopathic and irreversible loss of postganglionic
inhibitory neurons in Auerbach’s myenteric plexus.
15 The
resulting imbalance toward cholinergic stimulation
15,16
causes loss of LES relaxation and failure of the esophageal
body peristalsis after swallowing, giving the condition the
name achalasia, a Greek word meaning “failure to relax”.
There are no well described effects of achalasia outside
the abnormalities seen in the esophagus, LES, and the
vagus nerves.
17 Whether the failure of esophageal body
peristalsis is secondary to the obstruction caused by
nonrelaxing LES or is a primary defect of the esophageal
body is also still debated. Achalasia can present at any age,
but incidence increases during the second and third decades
of life. There is no evidence that the disease has a
predilection for a particular race or gender.
Despite considerable investigation, the cause of ganglion
cell degeneration in achalasia is still unknown. Possible
associations have been described with class II human
leukocyte antigen DQw1, implicating an autoimmune
mechanism
16 or an inflammatory reaction due to a viral
infection such herpes, measles, poliomyelitis, varicella
zoster, and human papilloma virus.
14,18,19 Supporting an
immune-mediated response to a virus in a genetically
susceptible population are data that from Boeckxstaens et
al.
20 who produced clonal proliferation of cytotoxic T cells
taken directly from the gastroesophageal junction (GEJ) of
patients with achalasia in response to herpes virus-1 (HSV-1).
As suggested by this evidence, a smoldering HSV-1 infection
could cause a myenteric plexitis and eventual self-mediated
neuronal destruction in a genetically susceptible patient.
Whether the mechanism of neuronal destruction is an
autoimmune or infectious process and which virus(es) can
lead to neuronal destruction is still unclear.
There is mounting evidence that the main downstream
effect of neuronal destruction is an alteration in the neuro-
transmitter nitric oxide (NO) pathway. NO is the dominant
small molecule mediating relaxation of the LES.
21 NO
activity decreases due to loss of the inhibitory neurons that
release NO and thus decreased relaxation of the LES.
22
These inhibitory neurons are thought to be severely
impaired, while interestingly, their cholinergic counterparts
are less affected.
23 In humans, this pattern was shown by
comparing the response of the LES in patients with
achalasia with that in healthy controls, after intravenous
injection of several well-defined pharmacologic stimuli.
The LES of achalasia patients was more sensitive than that
of healthy controls to methacholine and pentagastrin.
Edrophonium increased the LES pressure in achalasia
patients but had no significant effect on control patients,
whereas atropine increased the LES pressure in both
groups.
23 Furthermore, nitric oxide synthase (NOS) knock-
out mice display consistently higher resting LES pressure
and failure of relaxation of the LES in response to
swallowing,
24 which is a similar manometric pattern to that
of many patients with achalasia. Finally, GEJ biopsies from
patients with achalasia display a complete absence of NOS
containing neurons.
25
Ultimately, degeneration of the myenteric plexus
produces a functional defect causing loss of esophageal
body peristalsis and failure of relaxation of the LES in
response to swallowing. These abnormalities in motility
produce the slowed transit of solids and liquids, resulting
in the dysphagia that is most often the primary, but not
the sole complaint, of patients. Swallowed material pools
above the LES, causing irritation of the esophageal
mucosa and regurgitation, and may contribute to dilation
of the esophagus proximal to this outflow obstruction. In
addition to dysphagia and esophageal mucosal changes,
this pattern of dysmotility reliably produces manometric
and radiologic findings that are required for the diagnosis
of achalasia.
26–29
Diagnosis
The most common presenting symptom of achalasia is
dysphagia, which can often become so debilitating that
profound weight loss occurs. However, the primary
symptom of achalasia in up to 40% of patients may be
regurgitation of undigested food, unexplained chest pain,
“heartburn” mimicking reflux, cough, or recurrent pneumo-
nia. The standard current workup of a patient suspected of
having esophageal achalasia consists of a barium esopha-
gram, esophageal manometry, and upper endoscopy.
30
The barium esophagram can be a window into the static
structure and the dynamic function of the esophagus. The
mechanical outflow obstruction created by the LES leads to
dilatation of the esophageal body that narrows sharply to
form a classic “bird’s beak” appearance seen on esopha-
gram. Retained food is often seen in the esophagus and
transit of barium past the LES is slow. Radiographic
findings suggestive of achalasia have a specificity of about
75%.
17,31 As the disease progresses, often dilation worsens
and the esophagus can take on a sigmoidal shape with
S34 J Gastrointest Surg (2010) 14 (Suppl 1):S33–S45various degrees of dilation (Fig. 1). A sigmoid esophagus is
defined as dilation of the distal esophagus to more than
10 cm in diameter and/or one that takes a tortuous course
through the chest towards the GEJ. Another sign of
longstanding esophageal outflow obstruction is the devel-
opment of esophageal pulsion diverticula that produces
external compression on the esophagus (Fig. 2).
Standard stationary esophageal manometry is currently
the gold standard for diagnosing achalasia. Manometry is
important for differentiating achalasia from other esopha-
geal motility disorders such as diffuse esophageal spasm,
hypertensive LES, or nutcracker esophagus.
32 Findings on
manometry that suggest the diagnosis are (1) absence of
peristalsis of the distal two thirds of the esophageal body
and (2) incomplete LES relaxation in response to degluti-
tion.
33 The LES is hypertensive in approximately 50% of
cases,
34 but it can also be normo or hypotensive; conse-
quently, elevated resting LES pressure is not required for
the diagnosis of achalasia.
33 The diagnosis does require the
finding of an aperistaltic esophagus;
33,35 although aperis-
talsis of the esophageal body is not a finding specific to
achalasia, as it can be seen in diabetes, gastroesophageal
reflux disease, and collagen vascular diseases.
Manometric diagnosis of achalasia may be a challenge in
a small subset of patients with variants of the disease such
as vigorous achalasia. Vigorous achalasia is thought to be
an early stage of the disease.
36,37 LES pressure and the
amplitude of the simultaneous aperistaltic contractions are
significantly higher in vigorous achalasia than in “classic”
achalasia, and the repetitive (“mirror image”) waves are
more frequent.
38
Newer techniques such as high-resolution manometry
(HRM) and multichannel intraluminal impedance monitor-
ing can be used to study esophageal function and have
helped clinicians further classify patients with achalasia and
Figure 2 A barium esophagram
showing a normal caliber
esophagus with a large epi-
phrenic diverticula in a patient
with achalasia.
Figure 1 Examples of progressive dilation of the esophagus in
different patients with achalasia. a Normal diameter esophagus leading
to a bird’s beak at the LES. b Minimal esophageal dilation (from 4 to
7 cm). c Progressive esophageal dilation (from 7 to 10 cm) with
preserved esophageal axis. d Greater dilation (>10 cm) and initial
sigmoidal course of the distal esophagus.
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39,40 High-resolution manometry
records the pressure generated by the entire length of the
esophagus and reports this information as a topographical
plot. These data allow for more accurate definition of the
contractile elements of deglutition as they are traced from
the pharynx to the stomach.
41,42 In a recent study
evaluating 213 patients with achalasia, HRM was used to
classify the disease into three subtypes based on the
function of the contractile elements: In type I (classic)
achalasia (21.2% of patients), there was no distal esopha-
geal pressurization to greater than 30 mmHg in greater than
or equal to eight of the ten test swallows; in type II
achalasia (with compression; 49.5% of patients), at least
two test swallows were associated with an esophageal
pressurization to greater than 30 mmHg; and in type III,
patients (spastic; 29.3% of patients) had two or more
spastic contractions with or without periods of compart-
mentalized pressurization.
42 Using logistic regression, the
investigators related these subtypes to treatment response
and showed that patients with type II achalasia were the
least likely to report poor symptom improvement or require
further therapy within 12 months of the initial treatment.
Symptom relief was obtained in 71% of type II patients
after endoscopic injection of botulinum toxin (EBTI), 91%
after endoscopic dilation (ED), and 100% after Heller
myotomy. Type I patients had a good response to therapy
56% of the time, whereas type III patients had a good
response only 29% of the time.
42
Multichannel intraluminal impedance pH monitoring en-
tails positioning a series of electrodes inside the esophagus
and measuring the resistance to flow of electricity between
these electrodes.
43 If the esophageal lumen is filled with air,
the impedance is high relative to a lumen filled with fluid.
This test can also follow the dynamic impedance of a food
bolus after deglutition, and during the same swallow,
manometry results can be recorded. Achalasia results in a
dilated and fluid-filled esophageal lumen with slowed
transit of food boluses, so measuring the intraluminal
impedance adds to the information about the amplitude
and progression of muscle contractions gained from
manometry.
35,43
Patients being evaluated for achalasia often describe the
sensation of gastroesophageal reflux (GER) or heartburn,
either in addition to or in place of dysphagia. Most
achalasia patients likely do not have actual reflux of gastric
contents through the GEJ, but rather they experience this
sensation as a direct result of fermentation of retained food
in the distal esophagus and regurgitation. Fermentation is
the breakdown of carbohydrates into acids or alcohol under
the right conditions, and this can take place in the
esophagus of a patient with esophageal outflow obstruction.
Crookes et al.
44 showed that chewed samples incubated in
vitro with saliva but never exposed to gastric acid slowly
ferment. The pH of these samples gradually drops to
around 4, but usually not below that. They also showed
that achalasia patients can have pH tracings that mimic this
gradually decreasing pH, or they can have sharp dips in pH
more characteristic of actual reflux events. Therefore, to
make the diagnosis of reflux in a patient with achalasia, the
pH must drop below 3 or the tracing must display sudden
sharp drops in pH; otherwise, the decreasing pH is likely a
product of retained food fermenting in the distal esopha-
gus. This is an important diagnostic distinction because it
is the unusual patient who has both achalasia and GER.
Crookes et al. looked at 20 patients before surgery for
achalasia and found that five (20%) had abnormally high
esophageal acid exposure. Of those five patients, only one
(5%) had sudden pH drops characteristic of GER.
44
Evidence is lacking, but theoretically, these patients might
be at a higher risk for postprocedure reflux, and should be
counseled accordingly.
45
Diagnostic upper endoscopy must be performed in all
patients suspected having achalasia, although it may be
normal in up to 44% of cases.
17 It is an indispensable part
of the workup because primary, idiopathic achalasia must
be differentiated from secondary, or pseudoachalasia.
Endoscopy is required for this discrimination because
manometric findings in pseudoachalasia can be indistin-
guishable from those in primary achalasia.
46 Pseudoacha-
lasia can develop as a result of a parasitic infection by the
leishmanial forms of Trypanosoma cruzi (Chagas’ achala-
sia), which occurs most often in South Africa and South
America,
47,48 or in cases of a malignant disease of the distal
esophagus and the gastric cardia or peri-esophageal
tumors.
47–49 Pseudoachalasia has also been associated with
mesenchymal tumors, secondary amyloidosis, peripheral
neuropathy, or neurological disorders resulting from brain
tumors, lymphoma, and encephalitis.
31,50,51 Further causes
include iatrogenic conditions such as an incorrectly con-
structed or tight fundoplication during antireflux procedures
(ARPs) and placement of laparoscopic adjustable gastric
banding for the treatment of morbid obesity (Fig. 3).
31,50,51
Although rare, esophageal and gastric malignancies may
occur in patients with long-standing achalasia,
38,52 so a
retroflexed view of the GEJ with routine distal esophageal
and cardia biopsies should be obtained to ensure that all
mucosal abnormalities are identified. Furthermore, some
authors have recommended endoscopic ultrasound and/or a
computed tomography scan in older patients and patients
with advanced disease to uncover small, submucosal
lesions, which might otherwise go undetected by other
diagnostic tests.
53
Nonspecific findings on chest X-ray may include
mediastinal widening, presence of an air-fluid level in the
midesophagus, absence of a gastric air bubble, and
abnormal pulmonary markings due to chronic aspiration.
S36 J Gastrointest Surg (2010) 14 (Suppl 1):S33–S45After treatment, timed barium swallow (TBS) is an
additional tool to evaluate esophageal emptying and
correlate it with patient symptoms. During TBS, the patient
is instructed to drink 150 ml of barium as quickly as
comfortable within a time interval of 30 to 45 s. Spot films
of the esophagus are taken 1 and 5 min after ingestion of
the barium. The area of the barium column is measured on
timed digital images. Esophageal emptying is then calcu-
lated by comparing the area of the residual barium column
on the 1- and 5-min images.
54 Oezcelik et al.
55 evaluated
the TBS of 30 patients at 3 and 6 months after myotomy to
access esophageal emptying. They correlated the TBS
results with patient reported symptom relief and found that
esophageal emptying as measured by standard means did
not change significantly after myotomy, but initial esoph-
ageal clearance improved dramatically (by 81%) and this
correlated well with symptom improvement.
In summary, the diagnosis of achalasia is often suggested
by history, barium esophagram, and upper endoscopy.
Stationary esophageal manometry is currently the gold
standard. Because achalasia represents a spectrum of
disease, manometric findings can vary and the addition of
HRM, impedance manometry, and pH-impedance can
further classify the pathological state and may assist the
clinician during these diagnostic dilemmas. Twenty-four
hour pH monitoring can identify the unusual patient with
GER prior to treatment.
Treatment
Several treatment options for esophageal achalasia are
available. The overall health of the patient, coupled with
the patient’s expectations for symptom relief, must be
considered to ensure a proper treatment plan. Treatment
strategies attempt to relieve the obstructive nature of the
LES at rest and after swallowing, to allow a more normal
transit of liquids and solids, while taking great care not to
induce GER. Currently, there is no available treatment to
correct the dysmotility of the esophagus and LES created
by the disease. Treatment options consist of pharmacologic
therapy, endoscopic therapy, and surgery.
Pharmacologic Therapy
The goal of pharmacological therapy, the only noninvasive
treatment for achalasia, is to lower the resting LES pressure.
Because drug absorption is impaired due to the poor
esophageal emptying, sublingual medications are preferred.
Sublingual calcium channel blockers (nifedipine) and sub-
lingual isorbide dinitrates (nitrates) are the two most common
medications used.
56,57 Less commonly used medications
include anticholinergics, beta-blockers, beta-adrenergic ago-
nists (carbuterol, terbutaline, cimetropium bromide), nitro-
glycerine, and theophylline (aminophylline).
58–61
In collected outcomes for 229 patients treated with
pharmacologic therapy, we found that symptoms improved
in 61% of patients after use of nifedipine and 70% of
patients after use of nitrates.
116–123 Manometry was used to
document LES pressure before and after drug therapy in all
trials in different subsets of patients. A transient decrease in
LES pressure was documented in 46% of patients when
manometry was performed. This transient effect seemed to
be better after nitrate use than after nifedipine use, as
measured by the transient mean decrease in LES pressure
(baseline pressure−posttherapy pressure)×100, which was
66% after nitrates but only 38% after nifedipine. Nitrates
also seemed better than nifedipine with regard to the time to
maximum effect (25 vs 9 min), but the duration of effect
was longer for nifedipine (40 vs 30 min).
The short clinical response and common presence of side
effects such as headache, dizziness, tachycardia, hypoten-
sion, nausea, and ankle edema were limiting problems with
pharmacological therapy. It should be considered only for
patients who decline or are considered too frail for
endoscopic or surgical treatment options.
Endoscopic Therapy
Achalasia was first described in the literature in 1672 by Sir
Thomas William, and the first described treatment for
achalasia (then called “cardiospasm”) was performed in
London, by Thomas Willis. Of note, other notable
accomplishments of Thomas Willis include numbering the
cranial nerves and identifying the vascular arcade of the
brain that is now called the Circle of Willis. In 1674, he
described treatment of cardiospasm by forceful passage of a
Figure 3 A barium esophagram in a patient with a gastric band
causing pseudoachalasia. The esophagus is dilated and empties barium
slowly.
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LES.
62 With the advent of modern endoscopic techniques,
endoscopic dilation was first-line therapy for achalasia until
the advent of minimally invasive surgery in the 1980s.
63
Endoscopic treatments are directed at relieving the obstruc-
tion caused by the LES and now include endoscopic
botulinum toxin injection (EBTI), described in 1991,
64 or
endoscopic dilation (ED) of the LES.
EBTI decreases tonic and swallow-induced LES pressure
by inhibiting acetylcholine release from the inhibitory
cholinergic presynaptic nerve innervating the LES.
65 As
reported in a recent systematic review,
66 EBTI relieves
symptoms in 79% of patients surveyed up to 1 month after
treatment, but unfortunately, the symptom relief declines to
70% at 3 months, 53% at 6 months, and 41% after
12 months.
66 Due to this progressive return of dysphagia,
almost half (47%) of the patients undergoing EBTI required
repeat injection.
66 Relief of dysphagia was found to be
somewhat better if a second injection was planned at a
1-month interval after the first, but again, symptom relief
was not durable and symptoms returned in 66% of patients
at 2 years.
67 Primary failure of EBTI can also be due to
antibody formation that causes resistance to the acetylcho-
line injection in 26% of patients.
68–70 In addition to these
primary failures, EBTI leads to fibrosis of the mucosa and
muscle layers that could make the myotomy, during a future
surgical therapy, considerably more challenging.
71,72
The other mode of endoscopic therapy is ED, and the
current method of choice for dilation is a controlled pneu-
matic dilation.
63,73–75 Other older dilation methods have
gradually been abandoned as they were associated with a
higher perforation rate.
66 During controlled pneumatic
dilation, a balloon is placed across the LES under direct
endoscopic or fluoroscopic visualization. The balloon is
inflated for 1 to 3 min, to a pressure of 300 mmHg (10–
12 psi). To obtain an acceptable therapeutic effect, dilation to
a diameter of at least 3.0 up to 4.0 cm must be performed.
The goal of ED is similar to the goal of any surgical
therapy, as they both attempt to produce a controlled
division of the esophageal muscle while leaving the mucosa
intact. Review of the literature shows that dilator size, the
amount of pressure applied, and duration of dilation were
inconsistent between endoscopists and symptom relief
seems to be dependent on these variables. ED is a relatively
safe procedure and the most serious complication of the
currently used methods of ED is perforation of the
esophagus, which was seen in 1.6% of patients in a review
of 1,065 patients, but the perforation rate can be as high as
12% using older dilation techniques.
66 Symptom relief has
been related to the ability of the procedure to decrease the
resting LES pressure by more than 10 mmHg, or produce a
reduction of ≥50% of LES pretreatment pressure.
76
A recent Cochrane Review, published in 2008, com-
prised of six randomized controlled trials including 178
patients, looked at symptom recurrence after ED vs EBTI at
1, 6, and 12 months after treatment. This review found that
30% of patients undergoing ED experienced symptom
recurrence and treatment failure at 12 months vs 74% of
EBTI patients.
77
A recent systematic review and meta-analysis of 105
articles reporting on 7,855 patients treated for achalasia
showed that symptom relief after ED was obtained in 85%
of patients at 1 month and declined with time to 68% at
12 months and 58% at 1.5 years (Table 1).
66 Symptom
relief was better for ED than for EBTI (68% vs 41%, odds
ratio (OR) 3.4; 95% confidence interval (CI) 1.2–9.8; P=
0.02), and the need for further procedures was lower after
ED than after EBTI (25% vs 47%; OR 2.6; 95% CI 1.05–
6.5; P=0.04).
66
In addition to dysphagia recurrence, patients undergoing
ED can experience the onset of GER, with 33% of patients
reporting symptomatic GER at 4 years.
78–80 When 24-h pH
monitoring was used as a proxy, more than 30% of patients
had an increase in episodes and duration of reflux.
44,81
In summary, published evidence shows that ED is
consistently more durable than EBTI, but that after ED,
symptoms recur in 42% of patients and about 30% of all of
the patients treated with ED require further therapy. Prior to
any surgical intervention, knowledge of the patient’s history
of previous endoscopic therapies at the GEJ is important to
the surgeon because some experts propose that ED and
EBTI lead to fibrosis of the mucosa and muscular layers of
Table 1 Symptom Improvement After Initial Treatment of Achalasia by Therapeutic Endoscopy (Adapted from Campos et al.
66)
Treatment Number of
studies
Number of
patients
Symptom improvement at (numbers are mean
a % and range)
≤1months 3months 6months ≥12months ≥36months
Endoscopic injection of
botulinum toxin
9 315 78.7 (64–93) 70.0 (55–83) 53.3 (44–57) 40.6 (10–55) n/a
Endoscopic pneumatic
balloon dilation
15 1,065 84.8 (56–97) n/a 73.8 (51–97) 68.2 (38–90) 58.4 (33–70)
n/a data were not recorded for these time points in the studies used to compile the systematic review and meta-analysis
aWeighted averages of the sample prevalence in each of the studies, with weights equal to the number of patients
S38 J Gastrointest Surg (2010) 14 (Suppl 1):S33–S45the esophagus. Less predictable symptom relief has been
reported in patients who have been previously treated with
endoscopic therapy,
72,82 which could be due to the greater
technical difficulty of doing the operation in these patients.
To avoid mucosal perforation in these cases, the location of
the GEJ and the proper dissection planes must be identified
during the myotomy.
Surgical Therapy
The initial attempts to treat achalasia with an operation in
the early twentieth century combined several modifications
of gastroesophageal junction reconstructions (cardioplas-
ties) to esophageal resections.
83 Those techniques failed
due to high operative morbidity and excessive postopera-
tive gastroesophageal reflux and led to the development of
distal esophageal myotomy. The first successful surgical
myotomy of the lower esophagus and lower esophageal
sphincter was reported in 1913, by the German surgeon
Ernest Heller.
84 His original technique used anterior and
posterior myotomies extending for 8 cm or more along the
distal esophagus and GEJ through a left thoracoabdominal
approach. Although this technique was successful in
improving dysphagia, excessive gastroesophageal reflux
resulted. In 1918, the Dutch surgeon Zaaijer
85 described a
modification of Heller's original technique to a single,
anterior cardiomyotomy that has remained the myotomy of
choice until now. Based on Heller’s original idea, many
surgeons performed the distal esophageal and LES myot-
omy through a left thoracotomy
86 as a way to perform an
appropriate myotomy while attempting to preserve the
natural anatomical antireflux components of the gastro-
esophageal junction, such as the His angle and the
phrenoesophageal membrane, thereby possibly preventing
postoperative GER. Both the transabdominal and transtho-
racic techniques have been used since.
The end of the last century witnessed the shift from open
surgery in the chest and abdomen towards thoracoscopic
and laparoscopic surgery. The myotomies performed
through both approaches have evolved in parallel
87,88 into
minimally invasive procedures through the chest and
abdomen. The first laparoscopic Heller myotomy was
described by Shimi et al. in 1991.
89
One advantage of the transabdominal operation is that it
makes it easier to create a fundoplication because better
exposure of the structures of the GEJ can be obtained.
Thoracoscopic myotomy is also more technically challeng-
ing the transabdominal, because the myotomy must be
performed perpendicular to the course of the esophagus.
Finally, as discussed below, the thoracoscopic approach is
associated with a higher incidence of postoperative GER,
making the laparoscopic operation the preferred approach
performed at most experienced centers.
87,90,91
A 2009 systematic review and meta-analysis of the
surgical options summarized 64 articles, including 4,871
patients (Table 2).
66 Regression analysis confirmed that the
laparoscopic approach yielded similar symptom relief to the
open thoracic operation (89% vs 83%; OR 1.3; 95% CI
0.8–2.0; P=0.3) and the open abdominal operation (89% vs
84%; OR 1.1; 95% CI 0.5–2.5; P=0.8), but better relief
than then the thoracoscopic operation (89% vs 78%; OR
1.9; 95% CI 1.1–3.7; P=0.048) and also ED (89% vs 56%;
OR 5.9; 95% CI 3.7–9.3; P=<0.01).
66
In a recently published study of over 400 consecutive
patients, Zaninotto et al. reported their experience with
laparoscopic Heller myotomy and Dor fundoplication.
Similar to results previously reported by other authors,
92,93
the best predictor of a dysphagia relief was preoperative
LES pressure >30 mmHg.
94
Some authors have debated the need to perform an ARP
after the myotomy.
95–97 The 2009 systematic review and
meta-analysis also evaluated the development of postoper-
ative GER and found that adding an antireflux procedure
after laparoscopic myotomy dramatically decreased the
incidence of GER symptoms from 31% down to 9% (OR
4.3; 95% CI 1.9–9.7; P=0.001) without altering the resolu-
Table 2 Results (Symptom Improvement and Postoperative GER) After Surgical Treatment for Achalasia (Adapted from Campos et al.
66)
Treatment Months
follow-up
(range)
Number of
studies
Number of
patients
Mean symptom improvement
a
% (range)
Mean prevalence
a of GER
(range)
No ARP With ARP No ARP With ARP
Transthoracic myotomy 102.0 (57–172) 13 842 85.1 (66–97) 80.2 (66–97) 29.2 (4–66) 13.6 (0–28)
Thoracoscopic myotomy 36.4 (12–72) 8 211 77.6 (31–94) n/a 28.3 (15–60) n/a
Transabdominal myotomy 87.4 (8–190) 10 732 64.4 (57–66) 89.7 (73–100) 28.5 (21–64) 7.5 (0–15)
Laparoscopic myotomy 35.4 (8–83) 39 3,086 89.9 (86–100) 90.3 (77–100) 31.5 (11–60) 8.8 (0–44)
ARP antireflux procedure, n/a data not collected for at that time points in the studies used to compile the meta-analysis, GER postprocedure
gastroesophageal reflux symptoms
aWeighted averages of the sample prevalence in each of the studies, with weights equal to the number of patients
J Gastrointest Surg (2010) 14 (Suppl 1):S33–S45 S39tion of dysphagia (90% vs 90%; OR 1.6; 95% CI 0.74–3.3;
P=0.23).
66 When measured by 24-h pH monitoring, the
incidence of GER after laparoscopic myotomy without
fundoplication was 42% vs 15% after laparoscopic myotomy
with fundoplication (OR 4.2; 95% CI 1.5–12.8; P=0.01).
The addition of an ARP seems crucial for satisfactory
outcome in the treatment of achalasia, and the addition of a
fundoplication does not increase morbidity.
98–100
Selecting the proper treatment course for a given patient
requires analysis of the rates of complication of all of the
treatment options. With pneumatic balloon dilation, cur-
rently the accepted standard, the perforation rate is 1.6%.
66
Systematic review of the results of 3,086 patients who had
laparoscopic myotomy found that complications were
reported in 6% and death in 0.1%.
66 Intraoperative
perforation of the esophageal or gastric mucosa was
reported in about 7%.
66 Most of those injuries were
repaired during the index operation, and only 19 patients,
or 0.7%, experienced symptoms from perforation postop-
eratively. When overall complication rates reported after
laparoscopic myotomy are compared with ED, differences
are possibly related to an innate more invasive nature of the
laparoscopic surgery, but differences in baseline patient
characteristics and severity of the disease likely have an
impact on the results of each method reported. A 2001
decision analysis for the treatment of achalasia evaluated
four strategies for the initial management of achalasia: (1)
laparoscopic Heller myotomy and partial fundoplication,
(2) pneumatic dilatation, (3) botulinum toxin injection, and
(4) thoracoscopic Heller myotomy
101. According to the
analysis, laparoscopic myotomy with fundoplication was
the proper first treatment strategy unless the patient’s risk of
operative mortality was higher than 0.7%.
Surgical Technique
Laparoscopic Myotomy
Laparoscopic myotomy has proven over time to be the
approach that consistently produces the most durable
symptom relief.
99,100 The operation begins with trocar
placement similar to that for any laparoscopic operation
taking place at the GEJ.
100 The gastrohepatic ligament and
the phrenoesophageal membrane are opened to expose the
esophagus. The anterior vagus nerve is carefully identified
and preserved as the dissection is carried out in clockwise
fashion around the anterior esophagus. The anterior fat pad
covering the GEJ may be removed to facilitate the
myotomy.
In most cases, posterior esophageal dissection is not
needed. Leaving the posterior attachments intact also
provides an anchor to help keep the GEJ in the proper
anatomic location. A posterior dissection is only performed
in patients who have large concomitant hiatal hernias so
that the hernia can be reduced into the abdominal cavity
and the crura can be repaired properly.
The myotomy is begun by bluntly dividing the longitudi-
nal muscle fibers of the esophagus with graspers (Fig. 4),
scissors, or the hook. The myotomy is carried cephalad for
at about 6 cm and through the longitudinal and circular
muscle fibers down to the esophageal submucosa and
extended 2 cm in the caudal direction from the GEJ on the
anterior stomach to ensure complete division of the sling
fibers, making the total length of the myotomy about 8 cm
(Fig. 5). A gastric extension that is too short is one important
cause of failure of the myotomy to relieve dysphagia. The
gastric extension is also the part of the myotomy where the
most mucosal perforations occur because the plane between
the submucosa and the muscularis is not as pronounced in
this location. Any mucosal perforation should be primarily
repaired with interrupted absorbable suture.
Antireflux Procedure
After the myotomy is completed, an antireflux procedure is
performed to prevent postoperative GER by recreating the
His angle and keeping the GEJ inside the abdominal cavity.
A 360° Nissen fundoplication has been used in selected
series;
98,102,103 however, a Nissen fundoplication may
hinder esophageal clearance, resulting in progressive
postoperative dilatation of the aperistaltic esophagus and
recurrent dysphagia. Although a few centers with signifi-
cant experience in esophageal surgery still advocate a
Nissen fundoplication after myotomy,
103 most do not
recommend it due to reported reoperation rates as high as
29%.
10,32,86,104–108
Figure 4 The anterior vagus nerve (arrow) is identified and
preserved. Then two graspers are used to begin the myotomy just
above the GEJ.
S40 J Gastrointest Surg (2010) 14 (Suppl 1):S33–S45Two partial fundoplications have been used with
equipoise, a posterior fundoplication (Toupet fundoplica-
tion) and an anterior fundoplication (Dor fundoplication).
The Toupet fundoplication seems to provide an appropriate
antireflux barrier. The theoretical advantages of the Toupet
fundoplication are that due to its anatomical configuration,
(1) it keeps the edges of the myotomy pulled apart, thus
preventing scarring and recurrent dysphagia, and (2) that it
can be performed just after the lower esophagus has been
pulled downward and straightened, thus improving passage
through the cardia and again minimizing postoperative
dysphagia.
109 The drawbacks of the Toupet fundoplication
are the need for circumferential dissection of the gastro-
esophageal junction and the possibility that diverticula will
develop at the site of the myotomy years after surgery
because the fundoplication does not cover the myotomy
site.
110
Proponents of the Dor fundoplication argue that the
procedure is faster because the posterior esophageal attach-
ments may be left in place.
109 Another advantage is that a
properly constructed Dor fundoplication can prevent post
operative reapproximation of the myotomy.
111 Furthermore,
covering the myotomy with the fundoplication may seal
inadvertent mucosal injury and prevent future development
of diverticulae at the site of the myotomy. The Dor
fundoplication is described in detail elsewhere,
100 and it is
described briefly below.
Dor Fundoplication
The creation of the fundoplication begins with a complete
mobilization of the fundus of the stomach, including
division of the short gastric vessels all the way to the His
angle. This dissection is required to permit the creation of
the proper geometry of the fundoplication. Two vertical
rows of sutures secure the gastric fundus to the left and
right edges of the myotomy to create the fundoplication.
Initially, the inferior edge of the left side of the esophageal
myotomy is sutured to the medial gastric fundus. Then
Figure 6 The creation of a Dor fundoplication. The first suture from
the anterior portion of the fundus to the left edge of the myotomy
(arrow 1). The second suture will anchor the fundoplication and part
of the myotomy in the abdomen by apposing the fundus (arrow 2)
to the left crus (not shown) and then to left edge of the myotomy
(arrow 3).
Figure 7 The completed Dor fundoplication. Arrows 1 and 2 show
the suture line that anchors the fundoplication to the right edge of the
myotomy. Arrow 2 incorporates the fundus, the right crus to the right
edge of the myotomy. Arrow 3 points the suture that secures the
fundoplication to the diaphragm. Arrow 4 points to the divided short
gastric vessels that are brought into an anterior position as the
fundoplication is created. This reinforces the need for a complete
mobilization of the gastric fundus for the proper configuration of the
fundoplication.
Figure 5 A completed 8-cm myotomy is shown. Arrow 1 points to
the anterior vagus nerve. Arrow 2 points to the left edge of the
myotomy. Arrow 3 points to the exposed esophageal submucosa.
J Gastrointest Surg (2010) 14 (Suppl 1):S33–S45 S41(Fig. 6), a stitch is placed from a superior portion of the
gastric fundus to the left diaphragmatic crus and then
the left side of the myotomy about 2 to 3 cm cephalad of
the first suture. Two to 3 cm cephalad to the previous
suture, a suture secures the left side of the myotomy to the
gastric fundus without incorporating the crus. Attention to
the geometric arrangement of the fundus produced during
this step is important because the reconstructions of the His
angle, in addition to having an intra-abdominal GEJ, are
what provide the major antireflux barriers. A final suture,
again on the left and cephalad to the last, brings the fundus
to the left edge of the myotomy, this time just below the
myotomy apex.
100
A suture line is then created down the right edge of the
myotomy. The first suture secures the superior right edge of
the myotomy to a bite of gastric fundus. The suture line is
continued caudally down the right myotomy edge. The
second suture incorporates the right diaphragmatic crus to
the fundus and the myotomy edge. Two final sutures on the
right side bring the fundus to the inferior edge of the
myotomy, and the exposed mucosal surface should now be
completely covered by the fundus at this point. One or two
sutures should then be placed to secure the superior aspect
of the fundus to the anterior esophageal hiatus to prevent
anterior herniation of the fundoplication into the chest
(Fig. 7).
Persistent postoperative dysphagia can be the result of
the following technical factors: (1) the myotomy is too
short distally, (2) the myotomy is too short proximally, or
(3) the fundoplication has been constructed incorrectly.
Some patients may develop recurrent dysphagia after a
symptom-free interval. This type of failure may be due to
gastroesophageal reflux and the development of peptic
stricture, healing, and fibrosis of the distal portion of the
myotomy.
112
Treatment of advanced stages of achalasia is somewhat
controversial when the esophagus has dilated severely and
its course in the chest becomes sigmoidal. Some authors
have proposed that the gross pathology of the esophagus is
so advanced that it will not respond to myotomy and
fundoplication and therefore requires esophageal resection.
However, recent studies suggest that these patients may
have good outcomes after myotomy and fundoplication,
although studies with long-term follow-up are still lack-
ing.
113–115 Esophagectomy may need to be contemplated in
selected cases.
Summary
Achalasia is a debilitating motility disorder of the esoph-
ageal body and LES. The standard diagnostic workup
includes a barium esophagram, esophageal manometry, and
diagnostic upper endoscopy. The diagnosis cannot be made
without the finding of an aperistaltic esophagus on
manometry. Impedance testing and high-resolution manom-
etry may prove to be useful adjuncts in the future because
patient characteristics are highly variable at the time of
presentation. Achalasia can be treated with pharmacologic
therapy, EBTI or ED, or surgery. The treatment course
should be selected based on the patient’s age, overall state
of health, and expectations for recovery. Pharmacologic and
EBTI therapy can reduce dysphagia, but unfortunately,
symptom relief is often not durable. ED provides a longer
interval of symptom relief than EBTI, but dysphagia
commonly returns and often requires further intervention.
ED was considered first-line therapy for achalasia until the
late 1980s, when minimally invasive surgery was intro-
duced. Most centers have since adopted the laparoscopic
Hellermyotomywithapartialfundoplicationastheprocedure
of choice for treating achalasia. This operation provides
durable symptom relief with a low rate of complications and
infrequent development of postoperative GER.
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